# A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers

> **NCT01286103** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Canagliflozin 300 mg once daily and 150 mg twice daily
- **DRUG:** Canagliflozin 100 mg once daily and 50 mg twice daily

## Key facts

- **NCT ID:** NCT01286103
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** —
- **Final completion:** 2011-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2012-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01286103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01286103, "A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01286103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*